5 citations
,
July 1991 in “Irish Journal of Medical Science (1971 -)” Immunosuppressive therapy helps manage autoimmune diseases but carries risks like infection and potential for malignancy.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
1 citations
,
June 2017 in “Skin” Apremilast may help treat lichen planopilaris and frontal fibrosing alopecia when other treatments fail.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
4 citations
,
April 2024 in “Journal of Drugs in Dermatology” Ruxolitinib cream may help treat severe hair loss in children.
13 citations
,
April 2020 in “European Journal of Dermatology” Apremilast showed mixed results for treating severe alopecia areata.
3 citations
,
January 1985 in “British Journal of Dermatology” Zinc sulphate solution was not effective in reducing the number, duration, or severity of recurrent herpes simplex infections.
September 2023 in “Journal of the American Academy of Dermatology”
2 citations
,
March 2015 in “Clinical and Experimental Dermatology” Azathioprine can cause unusual hair loss, which may reverse after stopping the drug.
4 citations
,
May 2019 in “Sultan Qaboos University Medical Journal” Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
278 citations
,
March 2013 in “Gut” Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.
2 citations
,
April 2022 in “Cutaneous and Ocular Toxicology” Tofacitinib may help treat hair loss in children with alopecia areata.
36 citations
,
May 2004 in “The journal of small animal practice/Journal of small animal practice” Combining cyclosporine A and ketoconazole can effectively treat anal furunculosis in dogs, with some experiencing recurrences and mild side effects.
May 2018 in “The Journal of Immunology” A(1-7) treatment reduces symptoms of lupus in mice.
156 citations
,
August 2014 in “Cochrane library” Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
11 citations
,
March 2010 in “PubMed” IV cyclophosphamide effectively treated severe lupus nephritis in Indian patients.
13 citations
,
June 2008 in “International Journal of Dermatology” Sorafenib can cause a unique skin reaction.
May 2025 in “Reactions Weekly”
185 citations
,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
21 citations
,
January 2022 in “Pharmaceutics” Colchicine might help treat different skin diseases, but more research is needed to confirm its effectiveness and safe dosage.
March 2024 in “Poster presentations” A woman with lupus and Kikuchi-Fujimoto disease improved with treatment.
June 2024 in “BioSCIENCE” Microinfusion of methotrexate can help treat frontal fibrosing alopecia.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
165 citations
,
September 2003 in “Toxicology and applied pharmacology” Blocking COX, especially COX-2, in the skin can reduce inflammation and pain and may help prevent skin cancer.
17 citations
,
January 2015 in “Dermatology online journal” A patient's grey hair regained color during treatment with adalimumab.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
25 citations
,
March 2021 in “Australasian Journal of Dermatology” Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
January 2024 in “Skin Research and Technology” Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.